anti-CD19 CAR T-cell therapy (THERAVECTYS)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug Nameanti-CD19 CAR T-cell therapy (THERAVECTYS)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesTheravectys Sa

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesTheravectys Sa

Active IndicationsN/A

Inactive IndicationsPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A